Sign in
Create a Profile
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Diseases and Conditions Researched
Non Small Cell Lung Cancer
What is the purpose of this trial?
This is a research study designed to look at the effects of an investigational chemotherapy drug, KD019, on non small cell lung cancer in comparison to a standard chemotherapy drug, Erlotinib ( Tarceva®).Participation Guidelines
Gender: Both
Click here for detailed participation information for this trial.
| Sponsor: | Kadmon Corporation, LLC |
|---|---|
| Study HIC#: | 1204010034 |
How will my information be used?
For more information about this trial, contact:
Elin Rowen
203-737-3630
Principal Investigator
Daniel Morgensztern
Anne Chiang
Emily A. Duffield
Marianne J Davies
Rebecca Sipples
Roy Herbst
Sarah B Goldberg
Scott Nicholas Gettinger
Thomas James Lynch
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.
